scholarly journals In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor

2021 ◽  
Author(s):  
Takehiro Ando ◽  
Mizuki Yamamoto ◽  
Yukio Takamori ◽  
Keita Tsukamoto ◽  
Daisuke Fuji ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
In Vitro Selection ◽  
Receptor Interaction ◽  
Rna Aptamer ◽  
Cytokine Storm ◽  
Interleukin 6 Receptor ◽  
Systematic Evolution ◽  
Exponential Enrichment ◽  
Selection Of

ABSTRACT Interleukin-6 (IL-6) binds to IL-6 receptor (IL-6R) subunit, related to autoimmune diseases and cytokine storm in COVID-19. In this study we performed Systematic Evolution of Ligands by Exponential enrichment (SELEX) and identified a novel RNA aptamer. This RNA aptamer not only bound to IL-6R with a dissociation constant of 200 nM, but also inhibited the interaction of IL-6R with IL-6.

In Vitro Selection of the RNA Aptamer against the Sialyl Lewis X and Its Inhibition of the Cell Adhesion

2001 ◽  
Vol 281 (1) ◽  
pp. 237-243 ◽  
Author(s):  
Sunjoo Jeong ◽  
Tae-Yeon Eom ◽  
Se-Jin Kim ◽  
Seong-Wook Lee ◽  
Jaehoon Yu
Keyword(s):  
Cell Adhesion ◽  
In Vitro Selection ◽  
Sialyl Lewis X ◽  
Rna Aptamer ◽  
Lewis X ◽  
Sialyl Lewis ◽  
Selection Of

scholarly journals In vitro selection of RNA aptamer to hemin

2008 ◽  
Vol 52 (1) ◽  
pp. 513-514 ◽  
Author(s):  
M. Liu ◽  
T. Kagahara ◽  
H. Abe ◽  
Y. Ito
Keyword(s):  
In Vitro Selection ◽  
Rna Aptamer ◽  
Selection Of

scholarly journals Aptamers selection for platelets using droplet digital PCR

2021 ◽  
pp. 100-103
Author(s):  
A.V. Blagodatova ◽  
◽  
K.V. Kochkina ◽  
M.A. Komarova ◽  
N.Y. Trofina ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Anticoagulant Activity ◽  
Digital Pcr ◽  
Droplet Digital Pcr ◽  
Platelet Glycoprotein ◽  
Systematic Evolution ◽  
Selection For ◽  
Exponential Enrichment ◽  
Selection Of

The aim of the research. To obtain aptamers-inhibitors of platelet glycoprotein IIb / IIIa receptors, blocking platelet aggregation. Material and methods. Th e selection of aptamers for IIb / IIIa receptors of platelets was carried out according to the SELEX method (Systematic Evolution of Ligands by Exponential Enrichment), modifi ed to select aptamers for a specifi c epitope. Th e method allows selection and in vitro evolution of aptamers with selectivity to a specifi c target from a large library of oligonucleotides. Th e affi nity of aptamers for platelet IIb / IIIa receptors was determined using fl ow cytometry. Results. Pools of aptamers of aptamers with high affi nity for IIb / IIIa platelet receptors were obtained. Th e study of the antiaggregation properties of the pools with the best binding showed that platelet aggregation was minimal when using the aptamers from the pool of the 5th round of selection. Th us, the aptamers of this pool have the greatest potential to be used as an analogue of a synthetic peptide that blocks thromboaggregation. Aptamers from this pool were taken for sequencing in order to obtain sequences of aptamers with the best antiaggregatory properties. Conclusion. Pools of aptamers with high affi nity for IIb / IIIa receptors of platelets and anticoagulant activity were obtained.

Aptamer Oligonucleotides as Potential Therapeutics in Hematologic Diseases

2019 ◽  
Vol 19 (10) ◽  
pp. 788-795
Author(s):  
Weibin Li ◽  
Meng Zhao ◽  
Huihui Yan ◽  
Kaiyu Wang ◽  
XIaopeng lan
Keyword(s):  
Clinical Trials ◽  
In Vitro Selection ◽  
Cell Disease ◽  
Anemia Of Chronic Disease ◽  
The Past ◽  
Systematic Evolution ◽  
Anemia Of Chronic Inflammation ◽  
Exponential Enrichment ◽  
Potential Therapeutics

: Aptamers are single-stranded DNA or RNA oligonucleotides generated by a novel in vitro selection technique termed Systematic evolution of ligands by exponential enrichment (SELEX). During the past two decades, various aptamer drugs have been developed and many of them have entered into clinical trials. : In the present review, we focus on aptamers as potential therapeutics for hematological diseases, including anemia of chronic inflammation (ACI) and anemia of chronic disease (ACD), hemophilia, thrombotic thrombocytopenic purpura (TTP) or VWD type-2B, and sickle cell disease (SCD), in particular, those that have entered into clinical trials

In vitro selection of a photoresponsive RNA aptamer to hemin

2010 ◽  
Vol 20 (9) ◽  
pp. 2964-2967 ◽  
Author(s):  
Mingzhe Liu ◽  
Hiroshi Jinmei ◽  
Hiroshi Abe ◽  
Yoshihiro Ito
Keyword(s):  
In Vitro Selection ◽  
Rna Aptamer ◽  
Selection Of

Aptamer and its role in diagnostics

2016 ◽  
Vol 5 (02) ◽  
pp. 4799 ◽  
Author(s):  
Abhishek Parashar
Keyword(s):  
Monoclonal Antibody ◽  
Toxic Chemicals ◽  
Rna Molecules ◽  
New Class ◽  
Systematic Evolution ◽  
Exponential Enrichment ◽  
Near Future ◽  
Selection Of ◽  
Better Than

Aptamers are new class of recognizing agents which are being used in diagnostics and therapeutics. They are single strand DNA or RNA molecules and are selected against targets by systematic evolution of ligands by exponential enrichment (SELEX) method. This method was developed in 1990 by Turk and Gold. These days high through put version of SELEX is being used for quick selection of aptamer, working on same principle that was developed in 1990. It is believed that in near future aptamers could replace monoclonal antibody. The biggest advantage of using aptamers is that the process is in vitro in nature and does not require the use of animals; further properties of aptamers are comparable or even better than antibodies. Aptamers based sensors can be used for detection of toxic chemicals, pathogens, antibiotics etc. Although they are in the preliminary stages of development, results are encouraging and it seems that aptamer research has a very bright future.

Sign in / Sign up

Export Citation Format

Share Document